Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Revenue (2016 - 2025)

Historic Revenue for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $227.8 million.

  • Ani Pharmaceuticals' Revenue rose 5358.32% to $227.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $826.9 million, marking a year-over-year increase of 4886.51%. This contributed to the annual value of $614.4 million for FY2024, which is 2620.29% up from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Revenue of $227.8 million as of Q3 2025, which was up 5358.32% from $211.4 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Revenue peaked at $227.8 million during Q3 2025, and registered a low of $11.2 million during Q1 2021.
  • Over the past 5 years, Ani Pharmaceuticals' median Revenue value was $116.5 million (recorded in 2023), while the average stood at $117.2 million.
  • In the last 5 years, Ani Pharmaceuticals' Revenue crashed by 7749.83% in 2021 and then skyrocketed by 47568.75% in 2022.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Revenue stood at $60.9 million in 2021, then surged by 54.66% to $94.2 million in 2022, then soared by 39.71% to $131.7 million in 2023, then skyrocketed by 44.75% to $190.6 million in 2024, then grew by 19.54% to $227.8 million in 2025.
  • Its Revenue stands at $227.8 million for Q3 2025, versus $211.4 million for Q2 2025 and $197.1 million for Q1 2025.